TITLE

News Watch

PUB. DATE
June 2005
SOURCE
European Chemical News;6/6/2005, Vol. 82 Issue 2150, p25
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents news briefs concerning pharmaceutical industry as of June 2005. Research agreement signed by Codexis with Bristol-Myers Squibb to improve biocatalyst activity for a new Bristol-Myers Squibb candidate; Commercial license agreement signed by Crucell and DSM Biologics with Ferring Pharmaceuticals; Thermoplastic polyurethane developed by Bayer MaterialScience for the production of films used to coat fabrics.
ACCESSION #
17402790

 

Related Articles

  • DSM Biologics and Crucell Enter Licensing Deal. Bryner, Michelle // Chemical Week;8/1/2007, Vol. 169 Issue 26, p19 

    The article reports that DSM Biologics and Crucell of Leiden, the Netherlands have entered into an agreement to license a manufacturing technology based on the companies' jointly developed PER.C6 cell line, to LFB Biotechnologies of Paris, France. LFB will use the licensed technology to develop...

  • MorphoSys Signs Cooperative Agreements.  // Pharmaceutical Technology;Oct2006, Vol. 30 Issue 10, p166 

    The article announces the license agreement signed by MorphoSys AG with Crucell NV and DSM Biologics. The agreement allows the former to use a cell line designed to produce clinical-grade material and develop its therapeutic human antibody program. The financial details of these agreements were...

  • World Briefs.  // Pharmaceutical Technology;Aug2008, Vol. 32 Issue 8, p22 

    The article offers world news briefs related to pharmaceutical industry. In Asia and Pacific, NovaMed Pharmaceuticals (Shanghai) and Pfizer China has formed a partnership in the oncology area in distributing oncology products throughout mainland China. In Europe, an agreement is made between DSM...

  • DSM and Crucell license antibody technology to Sartorius.  // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p16 

    The article reports on the licensing agreement accorded by DSM Biologics and Crucell NV with Sartorius Biotech GmbH. The two companies have agreed to a non-exclusive PER.C6 research licensing deal with Sartorius. In addition, Sartorius will use Crucell's key technology to assess monoclonal...

  • Pharma: Other News To Note.  // BioWorld Today;7/30/2013, Vol. 24 Issue 144, p11 

    This section offers biopharmaceutical sector news briefs including a 10-year agreement between Bristol-Myers Squibb Co. and Samsung Biologics that allows the latter to manufacture a commercial antibody cancer drug for the former, a positive opinion given by the European Committe for Medicinal...

  • CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.  // Worldwide Biotech;May2005, Vol. 17 Issue 5, p3 

    Reports on a PER. C6 cell line research license agreement signed by DSM Biologics with Japanese pharmaceutical company Mitsubishi Pharma Corp. in 2005. Benefit of the license agreement for Mitsubishi; Terms of the contract; Information on DSM Biologics.

  • COMPANY SPOTLIGHT - Bristol-Myers Squibb Company.  // PharmaWatch: CNS;May2009, Vol. 8 Issue 5, p23 

    The article presents a corporate profile for Bristol-Myers Squibb Co. (BMS) in the U.S. BMS is involved in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company engages in research collaborations and...

  • AUREUS PHARMA RENEWS/EXPANDS AURSCOPE DB LICENSING.  // Worldwide Databases;Dec2007, Vol. 19 Issue 12, p7 

    The article reports that Aureus Pharma, a provider of knowledge management solutions has announced that Bristol-Myers Squibb Co., has renewed its license to Aureus' AurSCOPE GPCR and also licensed its AurSCOPE Kinase and Ion Channel Knowledge databases. Jason Theodosiou, chief executive officer...

  • Licensing Negotiations--and Stale Cookies. Gordon, Maxwell // Chemical Heritage;Winter2004/2005, Vol. 22 Issue 4, p12 

    Provides information on the licensing negotiations of Bristol-Myers in Japan and Russia during the 1970s. Significance of scientist managers to the pharmaceutical industry; Details of the negotiations of Bristol-Myers with Microbial Chemistry Research Foundation in Tokyo, Japan and Nippon...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics